UBS Maintains Cardinal Health(CAH.US) With Buy Rating, Raises Target Price to $160
Cardinal Health Analyst Ratings
UBS Maintains Buy on Cardinal Health, Raises Price Target to $160
Citi Maintains Cardinal Health(CAH.US) With Hold Rating, Raises Target Price to $140
Citigroup Adjusts Price Target on Cardinal Health to $140 From $130, Maintains Neutral Rating
Cardinal Health (CAH) Receives a Hold From Citi
Morgan Stanley Maintains Cardinal Health(CAH.US) With Buy Rating, Maintains Target Price $142
BofA Securities Maintains Cardinal Health(CAH.US) With Buy Rating
Cardinal Health Is Maintained at Buy by B of A Securities
Cardinal Health Analyst Ratings
Leerink Partners Maintains Cardinal Health(CAH.US) With Buy Rating, Raises Target Price to $161
Mizuho Securities Maintains Cardinal Health(CAH.US) With Buy Rating, Raises Target Price to $150
Cardinal Health Analyst Ratings
Mizuho Maintains Outperform on Cardinal Health, Raises Price Target to $150
Baird Maintains Cardinal Health(CAH.US) With Buy Rating, Cuts Target Price to $153
Baird Adjusts Cardinal Health Price Target to $153 From $154, Maintains Outperform Rating
Jefferies Upgrades Cardinal Health(CAH.US) to Buy Rating, Raises Target Price to $150
Cardinal Health's Growth Potential Under New Management: Buy Rating Backed by Strong Earnings and Strategic Acquisitions
Cardinal Health Upgraded to Buy From Hold at Jefferies
Cardinal Health Is Maintained at Neutral by JP Morgan